Kimberly Chew will present, "Psychedelics: Clearing the New Frontier in Mental Health Therapy," at the Washington Health Law Summit on Monday, December 11, 2023.
Psychedelics show promise in treating anxiety, ADHD, PTSD, depression, and opioid and alcohol addiction. However, data are still limited, and the DEA classification of psychedelics impedes further research.
Psychedelics (psilocybin, LSD, and MDMA) are Schedule 1 drugs that have "no currently accepted medical use.” This classification creates obstacles to researching their safety and efficacy as therapeutics. It also limits funding and encourages states to enact their own laws, creating inconsistency. This panel will explore the research to date, permitted uses, and potential policy solutions.
For more information, visit the event website.